News | Heart Valve Technology | July 21, 2015

GlobalData Analyst: Edwards Lifesciences, Medtronic Devices to Redefine TAVR Space

Report notes Sapien 3, CoreValve Evolut R have corrected critical flaws of early models, demonstrate growing acceptance of TAVR

GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences

July 21, 2015 — The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve replacements (TAVR) devices will transform the U.S. market for TAVR procedures over the next decade, according to an analyst with research and consulting firm GlobalData.

According to Premdharan Meyyan, GlobalData's analyst covering medical devices, Edwards Lifesciences' Sapien 3 and Medtronic's CoreValve Evolut R have corrected some of the critical flaws inherent in earlier models, namely the Sapien XT and CoreValve. As a result, these devices have reduced mortality and complication rates in patients with severe aortic stenosis.

Meyyan said:"The FDA's Sapien 3 approval is expected to solidify Edwards Lifesciences' TAVR market lead. The company has improved upon Sapien XT's design by incorporating a polyethylene terephthalate skirt into its product, which minimizes the incidence of paravalvular regurgitation following valve implantation. GlobalData expects this feature to become an industry standard moving forward.

"Additionally, clinical data evaluating safety and efficacy of the Sapien 3 has proved strong so far, with 30-day outcomes from the PARTNER II trial demonstrating a 2.2 percent all-cause mortality rate in inoperable/high-risk patients, compared to the 3.5 percent rate in patients with the Sapien XT."

The analyst added that Medtronic's CoreValve Evolut R updates the original CoreValve design to include a thinner delivery system using a 14F sheath, compared to the original device's 18F sheath. This enables the product to be used in a wider range of artery sizes, expanding the treatment to a greater number of patients.

Unlike the Sapien 3, CoreValve Evolut R is fully repositionable and retrievable, allowing physicians greater control during the fitting procedure. Key opinion leaders have noted the product's easy-to use and intuitive repositionability function, which GlobalData also expects to see in future transcatheter valves.

Meyyan continued: "The approvals of the Sapien 3 and CoreValve Evolut R highlight the increasing adoption and acceptance of TAVR within the medical community as a standard treatment option for valvular heart disease patients.

"Furthermore, they will give Edwards Lifesciences and Medtronic an edge over other TAVR players, such as Boston Scientific and Symetis, which have also been attempting to seize shares in a growing market expected to be worth $3.02 billion by 2020," the analyst concluded.

For more information:

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Overlay Init